Antisense Therapy

P-Glycoprotein Inhibition Sensitizes Leukemic Cells to Chemotherapy

Published in Cancer Weekly, September 7th, 1998

Antisense (As) oligonucleotides targeting the multidrug resistance gene (mdr1) inhibited P-glycoprotein and sensitized human acute leukemic blast cells to chemotherapeutics.

Drug resistance is a major obstacle in cancer treatment and is associated with treatment failure. One of the mechanisms of multidrug resistance (MDR) involves the overexpression of the mdr1 gene product, P-glycoprotein (P-gp). Several strategies have been developed to eradicate MDR in P-gp-expressing cells.

Sayuri Motomura and colleagues from the Tokyo Women's Medical College; The Japanese Red Cross Center, The Research Institute of Tuberculosis; the University of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry